Search
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational[A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … [A259846,L46731] In patients with recurrent prostate cancer that require localized treatment, the use of <sup>18</sup>F-labeled ligands for positron emission tomography (PET) offers accurate diagnostic
Metamfetamine
go.drugbank.com/drugs/DB01577ApprovedIllicitInvestigationalWithdrawnIt is a scheduled drug in most countries due to its high potential for addiction and abuse. … The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.[L43942]
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationals Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients … Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseNalidixic acid
go.drugbank.com/drugs/DB00779ApprovedWithdrawnNalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseDexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnFor Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].
Aurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawnand others, which are far more effective. … Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate
Hydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedFDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy
Categories: Hormonal Contraceptives for Systemic UsePlazomicin
go.drugbank.com/drugs/DB12615ApprovedOn June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. … It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy [A33942].
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalMarketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.
Categories: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitorsBexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Categories: Retinoids for cancer treatment